Search Results 971-980 of 16338 for monoclonal antibody

1. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

   Have received any monoclonal antibody therapy directed at treatment of the patient's malignancy within 2 weeks prior to anticipated first dose. Have ...

2. Cough - Mayo Clinic

   Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · Nasal Cleaning · Neti pot: Can it clear my nose? No ...

3. High-dose vitamin C: Can it kill cancer cells? - Mayo Clinic

   Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · MRI · Muscle pain · Needle biopsy · Night sweats · No ...

4. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC - Mayo Clinic

   (including monoclonal antibodies). 3. Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or ...

5. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

   ... monoclonal antibodies, antibody drug conjugates, radioimmunoconjugates, or T-cell orother cell-based therapies: 4 weeks (2 weeks permissible before the ...

6. A Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination with Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) - Mayo Clinic

   Anti-CD20 monoclonal antibody;; An anthracycline-containing chemotherapy regimen. No evidence, suspicion, and/or history of central nervous system (CNS) ...

7. Pemigatinib to Treat Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations - Mayo Clinic

   ... monoclonal antibody, if eligible for this therapy;. Anti-EGFR (epidermal growth factor receptor) monoclonal antibody, if eligible for this therapy.

8. Immune globulin-hipp (subcutaneous route) - Mayo Clinic

   Description. Immune globulin-hipp injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral ...

9. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

   * Any previous treatment with anti-CD19 antibody, complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody * ...

10. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or ...